Consistent with our findings, recent studies revealed that the expression level of RSAD2 was markedly increased in the SLE samples compared with controls, which may act as a potential biomarker gene and therapeutic target for the treatment of SLE (40, 41). This evidence concerns the gene RSAD2 and systemic lupus erythematosus.